Asset Details
Do you wish to reserve the book?
Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways
Do you wish to request the book?
Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways
2017
Overview
Obesity increases sympathetic nerve activity (SNA) via activation of proopiomelanocortin neurons in the arcuate nucleus (ArcN), and this action requires simultaneous withdrawal of tonic neuropeptide Y (NPY) sympathoinhibition. However, the sites and neurocircuitry by which NPY decreases SNA are unclear. Here, using designer receptors exclusively activated by designer drugs (DREADDs) to selectively activate or inhibit ArcN NPY neurons expressing agouti-related peptide (AgRP) in mice, we have demonstrated that this neuronal population tonically suppresses splanchnic SNA (SSNA), arterial pressure, and heart rate via projections to the paraventricular nucleus (PVN) and dorsomedial hypothalamus (DMH). First, we found that ArcN NPY/AgRP fibers closely appose PVN and DMH presympathetic neurons. Second, nanoinjections of NPY or an NPY receptor Y1 (NPY1R) antagonist into PVN or DMH decreased or increased SSNA, respectively. Third, blockade of DMH NPY1R reversed the sympathoinhibition elicited by selective, DREADD-mediated activation of ArcN NPY/AgRP neurons. Finally, stimulation of ArcN NPY/AgRP terminal fields in the PVN and DMH decreased SSNA. Considering that chronic obesity decreases ArcN NPY content, we propose that the ArcN NPY neuropathway to the PVN and DMH is pivotal in obesity-induced elevations in SNA.
Publisher
American Society for Clinical Investigation
Subject
Agouti-Related Protein - biosynthesis
/ Agouti-Related Protein - genetics
/ Animals
/ Arcuate Nucleus of Hypothalamus - metabolism
/ Arcuate Nucleus of Hypothalamus - pathology
/ Arcuate Nucleus of Hypothalamus - physiopathology
/ Dopamine
/ Food
/ Mice
/ Neurons
/ Obesity
/ Paraventricular Hypothalamic Nucleus - metabolism
/ Paraventricular Hypothalamic Nucleus - pathology
/ Paraventricular Hypothalamic Nucleus - physiopathology
/ Peptides
/ Receptors, Neuropeptide Y - genetics
/ Receptors, Neuropeptide Y - metabolism
/ Rodents
/ Sympathetic Nervous System - metabolism
